home / stock / opti:cc / opti:cc news


OPTI:CC News and Press, Optimi Health Corp. From 02/06/23

Stock Information

Company Name: Optimi Health Corp.
Stock Symbol: OPTI:CC
Market: CNQC
Website: optimihealth.ca

Menu

OPTI:CC OPTI:CC Quote OPTI:CC Short OPTI:CC News OPTI:CC Articles OPTI:CC Message Board
Get OPTI:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

OPTI:CC - Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under GMP-compliant protocols, making additional MDMA product available for clinical research, drug...

OPTI:CC - Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and suppl...

OPTI:CC - Optimi Health Announces Re-Appointments to Board of Directors

VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilso...

OPTI:CC - Psychedelic Drugs Prove Their Worth In Clinical Trials

Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan for its lead psychedelic drug for the treatment of major depressive disorder after r...

OPTI:CC - Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. Highlights: $1.85 million in proceeds received through a strategic offering of units ...

OPTI:CC - Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable Carolyn Bennett, has publicly stated that safe drug supply is paramount to reducing...

OPTI:CC - Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from A...

OPTI:CC - Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psiloc...

OPTI:CC - Optimi Health Completes Largest Legal Harvest of Natural Psilocybin in Canadian History

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a homegrown Canadian company producing natural, scalable and accessible psychedelic and functional mushrooms and synthetic formulations for transformational human experiences. The company is on Health Canada’s list of ...

OPTI:CC - Optimi Health and Avida Global Sign First International Mushroom Supply Agreement

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a homegrown Canadian company producing natural, scalable and accessible psychedelic and functional mushrooms and synthetic formulations for transformational human experiences. The company is on Health Canada’s list of appr...

Previous 10 Next 10